Pietro Canetta is Associate Professor of Medicine at Columbia University. OpenAlex indexes 160 publications with 9,264 citations (h-index 42); ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 12 Oct 2026
Overview
Updated 14 Oct 2026
Pietro Canetta, M.D., is Associate Professor of Medicine at Columbia University. The public record shows 160 publications with 9,264 citations (h-index 42), centered on Renal Diseases and Glomerulopathies, Chronic Kidney Disease and Diabetes, Vasculitis and related conditions. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 9 companies.
- Most recent indexed publication: 2026 · Clinical journal of the American Society of Nephrology
- Top research focus: Renal Diseases and Glomerulopathies
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 24 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 77.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
Industry payments
Updated 14 Oct 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Otsuka Pharmaceutical Development & Commercialization, Inc.Program year20252 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
75%Loop diuretic20%Furosemide53%Torsemide47%Part D<11 patientsCalcium channel blocker16.2%Amlodipine Besylate100%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
25%SGLT2 inhibitor25%Jardiance65%Farxiga35%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Primary Glomerular Diseases in the Elderly: Clinical Features, Treatment Patterns, and Outcomes in the CureGN Cohort.
Clinical journal of the American Society of Nephrology
Article2026 - Author Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes.
Nature communications
Erratum2025 - Exome analysis links kidney malformations to developmental disorders and reveals causal genes.
Nature communications
Article2025 - Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis.
Clinical journal of the American Society of Nephrology
Article2025
Most-cited works
by citation count (OpenAlex)- 01Diagnostic Utility of Exome Sequencing for Kidney DiseaseArticle787 citations2018
- 02An atlas of healthy and injured cell states and niches in the human kidneyArticle745 citations2023
- 03
- 04Rituximab or Cyclosporine in the Treatment of Membranous NephropathyArticle617 citations2019
- 05Kidney Biopsy Findings in Patients with COVID-19Article414 citations2020
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/pietro-canetta-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
kidney.org/podcasts/kidney-commute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidney.org ↗ - Apple Podcasts
podcasts.apple.com/us/podcast/navigating-iga-nephropathy-insights-from-a-patient/id1505593513
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Board certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.nyp.org ↗ - Board certified
Nephrology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.nyp.org ↗ - M.D.
Columbia University College of Physicians and Surgeons
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.nyp.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.nyp.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.nyp.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.nyp.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Serge Przedborski, MD, PhD
Columbia University
Lawrence Honig, MD
Columbia University
Shonni Silverberg, MD
Columbia University
Jatin Vyas, MD, PhD
Columbia University
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)